We Partner 4 Research

: - At least 18 years old at time of consent - Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial - Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2). - Participants with medical history of hypertension and on active pharmacological treatment - Participants with medical history of type 2 diabetes mellitus (T2DM) and on active pharmacological treatment - Established cardiovascular (CV) disease and on active pharmacological treatment - At least one additional risk factor for developing heart failure (HF)

• History of HF or hospitalization for HF or treatment of HF - Atrial fibrillation or Atrial flutter with a resting heart rate >110 beats per minute (bpm) documented by echocardiogram (ECG) at Visit 1 (screening) - Advanced untreated conduction disease or untreated clinically relevant ventricular arrhythmia at Visit 1 (screening) - Treatment with an Mineralocorticoid receptor antagonist (MRA) - Treatment with amiloride or other potassium-sparing diuretic - Receiving the following treatments at Visit 1 (screening) or requiring such treatment before Visit 2 (randomisation), or planned during the trial: - A direct renin inhibitor (e.g. aliskiren) - More than one Angiotensin-converting enzyme inhibitor (ACEi) and/or Angiotensin receptor blocker (ARB) (including Angiotensin receptor-neprilysin inhibitor (ARNi)) used simultaneously - Other aldosterone synthase inhibitors (e.g. baxdrostat) - Systemic mineralocorticoid replacement therapy (e.g. fludrocortisone) Further exclusion criteria apply.